ZTS$126.65
$127
Chart
Performance
Key Stats
AI ZTS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyZoetis exhibits strong fundamentals in animal health, benefiting from growing pet care and livestock productivity trends. While valuation is on the higher side, consistent profitability and a solid balance sheet support a positive outlook. Technicals suggest a potential short-term pause in the uptrend.
Thematic
Zoetis is well-positioned to benefit from increasing global spending on animal health, driven by pet humanization trends and the need for enhanced livestock productivity and disease prevention. Innovation in diagnostics and biologics provides further tailwinds.
Fundamental
Zoetis demonstrates robust profitability and healthy cash flow generation. Its balance sheet is strong, with manageable debt levels. Revenue and earnings have shown consistent growth, though the P/E ratio suggests investor optimism.
Technical
The stock is trading within a defined range, with support near the $153 mark and resistance around $154. Momentum indicators are mixed, suggesting a potential period of consolidation before the next directional move.
| Factor | Score |
|---|---|
| Animal Health Market Growth | 90 |
| Pet Humanization Trend | 85 |
| Livestock Productivity & Disease Prevention | 80 |
| Innovation & R&D Pipeline | 88 |
| ESG Integration | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 92 |
| Growth | 75 |
| Balance Sheet Health | 90 |
| Cash Flow | 88 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 65 |
| Momentum | 55 |
| Support & Resistance | 75 |
| Volume Analysis | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
The company has consistently beaten EPS estimates in the last four reported quarters, with average positive surprises of 5.8%. This indicates strong earnings execution.
Attractive Forward P/E Ratio
The forward P/E ratio is 27.44, which is lower than the trailing P/E of 35.9, suggesting that future earnings are expected to grow and the stock may be reasonably valued based on future prospects.
Bearish Points (7)
High Trailing P/E Ratio
The trailing P/E ratio of 35.9 is relatively high, especially when compared to the reported net income for the TTM period ($1.89 billion). This suggests the stock might be overvalued based on current earnings.
Year-to-Date Decline
The stock is down 5.1% year-to-date (YTD), indicating underperformance compared to broader market indices and suggesting potential investor concerns or sector headwinds.
Calendar
July 2025
18
Ex-Dividend Date
August 2025
5
Next Earnings Date
H: $1.66
A: $1.61
L: $1.57
H: 2.44B
A: 2.41B
L: 2.37B
September 2025
3
Next Dividend Date
Profile
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
Seasonals
Price Target
194.10 USD
The 39 analysts offering 1 year price forecasts for ZTS have a max estimate of 238.00 and a min estimate of 160.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct, major global competitor in animal health, offering a wide range of products for livestock and companion animals.
Weight: 90
Operates Merck Animal Health, a significant global division directly competing with Zoetis in veterinary pharmaceuticals and vaccines.
Weight: 88
Leading provider of diagnostic products, equipment, and services for companion animals and livestock, crucial for veterinary practice.
Weight: 85
Dedicated animal health and nutrition company, offering products for livestock and poultry, a direct competitor in specific segments.